Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s Wakamoto, GSK Arm Team To Co-Market Botox

This article was originally published in PharmAsia News

Executive Summary

Japan's Wakamoto Pharmaceutical and U.K.-based GlaxoSmithKline's Japanese unit have reached a co-marketing agreement for GSK's Botox (botulinum toxin type A) beginning July 6. U.S.-based Allergan owns Botox, but GSK has the Japanese and Chinese rights to develop the drug, which has both cosmetic and medical uses, such as treating facial muscle spasms and eye blinking. With Wakamoto, GSK seeks to promote the drug for eye-related therapy. (Click here for more - a subscription may be required
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072078

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel